Background Risk of arrhythmic death is considered highest in ischemic heart disease with severe left ventricular ejection fraction (LVEF) reduction. Non-invasive testing should improve decision-making of prophylactic defibrillator (ICD) implantation.
Introduction
Randomized trials in patients with ischemic heart disease have shown that prophylactic implantation of a cardioverter-defibrillator (ICD) improves overall survival in selected patients with ischemic heart disease and markedly reduced left ventricular ejection fraction (LVEF) [1] [2] [3] . Prediction of sudden cardiac death and especially arrhythmic death (AD) based on arbitrary LVEF criteria (30% or less) has major limitations in accuracy. In patients with ischemic heart disease, non-invasive assessments of autonomic function [4] or electrophysiological markers [5] have been proposed to identify high-risk patients. Combining both assessments might enhance risk stratification [6] . There are limited prospective data available how combined assessment of autonomic and electrical substrate at single or multiple time points might improve ischemic heart disease management [7] . The objective of this paper was to evaluate the clinical relevance of a combined assessment of autonomic function plus cardiac electrical substrate at multiple time points for the prediction of fatal arrhythmias in patients with ischemic heart disease.
Methods
The local ethics committee approved this prospective observational, controlled, observer-blind study. All participants gave were not disclosed to participants or their physicians. Antiarrhythmic drug therapy and ICD implantation were not guided by the study.
Population
A total of 120 consecutive patients with a history of myocardial infarction and ischemic heart disease and 30 control subjects without myocardial infarction and ischemic heart disease were studied. Patients were eligible to participate if they were at least 18 years of age, had an LVEF of 50% or less due to a myocardial infarction within the last 2 months or a normal LVEF (controls, no myocardial infarction), had recently undergone coronary angiography with ventriculography due to suspected myocardial infarction, had no history of sustained ventricular arrhythmia or permanent atrial fibrillation and were non-dependent on ventricular pacing. Coronary angiography with ventriculography as standard use of care in symptomatic patients with suspected coronary artery disease was independent from study participation and was not guided by the study.
Cardiac pump function
Left ventricular ejection fraction was initially calculated from echocardiography and ventriculography following coronary angiography (screening). LVEF was then reassessed by radionuclide angiography or by magnetic resonance imaging (gold standard) at enrolment which was close to I1, followed by a reassessment of LVEF close to I2 and thereafter every 2 years.
Cardiac electrical substrates
Corrected QT-times with Bazett's formula (QTC) were obtained using automated analysis systems. Non-sustained ventricular tachycardia (nsVT) and signal-averaged ECG (SAECG) were obtained using 24-h Holter monitoring devices. NsVT was defined as a run of ≥ 3 ventricular beats lasting no longer than 30 s without syncope. SAECG were obtained by time-domain analysis as previously described [8] . Late potentials were present if two of the following criteria were fulfilled: QRSf > 114 ms, LAS40 > 38 ms and RMS40 < 20 lV. Microvolt T-wave alternans (MTWA) was assessed during submaximal bicycle exercise (CH 2000 â ;
Cambridge Heart Inc., Bedford, MA, USA). Patients continued their regular cardiovascular medications except betablockers which were withheld on the day of the investigation. The MTWA test was automatically interpreted (Version D10) and verified. Standard invasive programmed ventricular stimulation (PVS) provided up to three extra stimuli delivered during sinus rhythm and after eight paced ventricular cycle lengths at 500, 430, 375 and 333 ms [9] . The positive procedural endpoint of PVS was the induction of a sustained monomorphic VT. PVS was performed in all patients with coronary artery disease except those with a clear ICD indication (patients with severely reduced LVEF).
Autonomic function
For baroreflex testing, continuous finger blood pressure by the vascular unloading technique, beat-to-beat stroke volume by impedance cardiography and four lead ECG was recorded with the Task Force Monitor_system (TFM â ; CNSystems, Graz, Austria) [10] . After a resting period in supine position of at least 30 min, three bolus injections of Phenylephrine (2-4 lg/kg) were given intravenously at intervals of 10 min to raise systolic blood pressure by 15-40 mmHg [4] . A regression line was fit between data pairs of blood pressure and R-R intervals. Only regression lines with a R 2 coefficient either more than 0Á80 or statistical significant linear regression (Ftest on the regression model, P < 0Á05) were accepted. Baroreceptor reflex sensitivity (BRS, ms/mmHg) was obtained by calculating the mean from at least three slope determinations. Short-time spectral measurement of low frequency (LF) and high frequency (HF) of heart rate variability (HRV) was obtained during a 10-min resting period in supine position before pharmacological baroreflex testing [11] . Normalized values as well as LF to HF ratio (LF/HF) were analysed. Time-domain measures and long-term spectral parameters of HRV were obtained from 24-h Holter recordings. The standard deviation of all normal-to-normal R-R intervals (SDNN) was chosen as one of the favourite time-domain parameter for the statistical model analysis.
Endpoints, classification of death
The primary endpoint was time to arrhythmic death (AD) or resuscitated cardiac arrest (RCA). Cardiac death (CD) and allcause mortality were secondary endpoints. Deaths were categorized utilizing an adapted form of the Hinkle classification [12] . Appropriate ICD therapy without VT acceleration that failed to save the patient's life at the time of arrhythmias was classified as AD. An RCA was ventricular fibrillation or VT > 240 bpm leading to syncope before ICD therapy, and multiple slower VT episodes (electrical storm) leading to syncope and ICD discharge without ICD therapy related acceleration. All other ICD therapies due to VT < 240 bpm were not taken as surrogate for AD. All ICD devices were programmed to allow maximum possible detection duration.
Sample size justification and statistical analysis
The accrual interval is 1 year with additional follow-up of 10 years. Based on our prior knowledge and literature review, the median survival time for ischemic heart disease patients was 15 years. If the true ratio (relative risk) of controls relative to ischemic heart disease patients is 0Á4, we need to study 120 ischemic heart disease patients and 30 control patients to be able to reject the null hypothesis that the survival curves are equal with 89% power. The Type I error probability associated with this test of this null hypothesis is 0Á05. Data were summarized as median with first and third quartiles or percentage (N) for continuous and categorical variables. Wilcoxon rank-sum test or KruskalWallis test was used for continuous variables, and chi-square test was used for categorical variables. Survival curves were estimated by cumulative incidence treating death as the competing event, and the k-sample test was used. To assess whether MTWA, BRS or SDNN adds prognostic value in addition to LVEF, we fit four separate Cox proportionalhazards models (all adjusted for age and gender). The added prognostic value was assessed by likelihood ratio test. All tests were two-tailed with 5% significance level. All analyses were performed at the Vanderbilt University School of Medicine, Department of Biostatistics, Nashville, TN, USA using an open-source software R version 3.0.2 as previously described [13] .
Results
A total of 120 ischemic heart disease patients with LVEF of 50% or less and 30 control patients with a normal LVEF underwent serial clinical testing ( Fig. 1 , upper part). Distribution of LVEF and clinical characteristics of the two patient groups are listed in Table 1 . The median LVEF was 34% in ischemic heart disease patients. During a median follow-up period of 7Á5 years, 46 A total of 150 patients (120 ischemic heart disease patients (ICM) with LVEF =< 50%, 30 controls with LVEF > 50%) underwent serial testing. They were enrolled from a larger sample of consecutive patients. Ineligibility was mainly due to permanent atrial fibrillation. Other patients refused participation or LVEF normalized. During a median follow-up of 7 years, 46 (45 ICM patients and one control patient) deaths were observed. Of these, 34 were categorized as cardiac and 18 as arrhythmic. In 22 patients, a resuscitated cardiac arrest was documented as their first event. Five of these 22 patients died during further follow-up from a non-cardiac and non-arrhythmic reason. (* marked as five non-qualifying events).
deaths (one in the control group) were observed. Of these, 34 were categorized as cardiac where 18 were considered as arrhythmic. In 22 patients, a RCA was documented as their first event (Fig. 1, left lower part) . Five of these 22 patients died within the follow-up period. In 35 out of 70 ICD recipients (50%), ICD therapies (22 RCA events and 13 VT < 240/min events) were recorded. No RCA occurred in non-ICD recipients. Out of 18 patients died from AD, 9 (LVEF < 30%) had an ICD implanted but the device could not abort an electrical storm. Another eight patients (LVEF ≥ 30%) had no ICD implanted, and one patient had a CRT-Pacemaker only. Mortality rates are shown in Table 2 .
Test results related to primary and secondary endpoints BRS and HRV testing at second investigation (I2), MTWA and LVEF at both investigations (I, I2) were significantly different associated with the primary endpoints of AD or RCA and other forms of death (Table 3 ). All studied test results at both investigations (I1, I2) were significantly different associated according to the secondary endpoints of cardiac (n = 21) and non-cardiac death (n = 3) ( Table 4 ). Figure 2 demonstrates that MTWA only was associated with AD or RCA (P < 0Á001, Fig. 2d ), but not BRS (Fig. 2e) and SDNN (Fig. 2f) . LVEF was a non-significant predictor for cardiac death (Fig. 2a ) and arrhythmic events: the cumulative incidence for arrhythmic death or resuscitated cardiac arrest was not dependent on LVEF. This was true for LVEF < 35% and ≥ 35% (P = 0Á093), < 30% and ≥ 30% (P = 0Á772, Fig. 2b ) and < 30% and 30-39% and 40-49% (P = 0Á289, Fig. 2c ). We fit a Cox proportional-hazards model for the association between LVEF and time to RCA and AD adjusted for age and gender. We added MTWA, BRS and SDNN to the EF model one at a time to test for possible higher prognostic value. A comparison of likelihood ratios between the 'LVEF+MTWA' model, 'LVEF+BRS' model, 'LVEF+SDNN' model and the LVEF only model revealed that only MTWA but not BRS or SDNN added predictive information (Table 5) . Sensitivity, specificity, positive predictive value and negative predictive value regarding AD or RCA for 'LVEF+MTWA' model for all patients were 83%, 78%, 64% and 91% regarding first assessment (I1) and 93%, 80%, 61% and 97% regarding second assessment (I2), respectively.
Other parameters in addition to LVEF
We performed likelihood ratio test for time to primary endpoints (arrhythmic death, resuscitated cardiac arrest) comparing three models ('LVEF+MTWA', 'LVEF+BRS' and 'LVEF+SDNN' model) to the LVEF only model with age and sex adjustments. The results indicate that MTWA adds more predictive values regarding to the primary endpoints in Missed patients at risk for AD or RCA and possible benefits from ICD therapy
Considering that all 120 patients with ischemic heart disease would receive an ICD, the treatment ratio would be 3 : 1 as there were 40 AD/RCA events. In addition, if one considers non-fatal VT in the setting of ischemic heart disease as an ICD indication, the percentage of patients benefitting from ICD will increase to 44% with a treatment ratio of 2Á3 : 1. Considering that 57 out of 120 patients with ischemic heart disease and a non-negative TWA result would receive an ICD, the ICD treatment ratio would be 2Á1 : 1. Considering that 33 out of these 57 patients had an AD/RCA event, the combination of LVEF+TWA would result in an ICD treatment ratio of 1Á2 : 1. The resulting percentage of ischemic heart disease patients missed at risk would be 35% for LVEF > 30% and 11% for TWA, respectively.
Discussion
To the best of our knowledge, this is the first prospective, longterm (follow-up 10 years) observational study on multiple risk stratification techniques for primary prophylactic defibrillator implantation in patients with ischemic heart disease and both preserved and clearly reduced left ventricular function. The main finding is that none of the investigated techniques including the degree of left ventricular dysfunction reliably could identify patients at risk for sudden arrhythmic death. The ACC/AHA/ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death dichotomize patients with ischemic heart disease according to the degree of left ventricular dysfunction: ICD therapy is recommended in patients with symptomatic heart failure (NYHA classes II-III) and LV ejection fraction ≤ 35% after ≥ 3 months of optimal medical therapy [14] . In patients with an ejection fraction of > 35%, the risk of sudden arrhythmic death is considered low not warranting primary prophylactic ICD implantation. Bigger et al. [15] . first described that ventricular arrhythmias and LV dysfunction are related, one at a time and jointly, to total mortality and to arrhythmic deaths. However, the mean follow-up period in this study has been 1Á7 years only. These findings subsequently formed the rationale for the primary prevention studies MADIT II and SCD-Heft that used an ejection fraction of 30% and 35% as upper limit for patient inclusion [3, 16] . In MADIT II and SCDHeft, primary preventive ICD implantation was associated with a significant absolute reduction in total mortality of 5Á6% and 5%, respectively. The follow-up period was with maximum of 1Á8 years in MADIT II and with median of 3Á8 years in SCD-Heft considerably short.
The most important finding of our study is that over a projected follow-up period of up to 10 years, the cumulative incidence of arrhythmic death and resuscitated cardiac arrest is not significantly different in patients with (EF < 30%) and without (> 30%) severe left ventricular dysfunction. This finding is regardless of the degree of EF reduction (EF of < 30%, EF between 30% and 39% and patients with EF of > 40%). Similar to the patients in the Multicenter Post-Infarction Group Trial, our patients with an ejection fraction of ≥ 30% had an excellent prognosis and virtually no risk of sudden arrhythmic death during the first 2 years of follow-up [15] . However, our findings differ after the initial 2 years of follow-up. Thereafter, even in this favourable subpopulation, the risk of arrhythmic events continuously increased to finally reach a virtually identical level of arrhythmic death or resuscitated cardiac arrest when compared to patients with severely depressed LV function.
A highly significant difference in total cardiac mortality was found by dichotomizing the study population in patients with an EF < 30% vs. > 30%. This excess in cardiac mortality in patients with left ventricular dysfunction may offset in part the gains made by the ICD and probably explains why in the Table 2 Primary and secondary endpoints stratified according LVEF Ischemic heart disease, LVEF < 30%, n = 37 Ischemic heart disease, LVEF 30-39%, n = 54 Ischemic heart disease, LVEF 40-49%, n = 29
Control subjects, n = 30
All-cause mortality n = 16 (43%) n = 18 (33%) n = 11 (38%) n = 1 (3%)
Cardiac death n = 14 (38%) n = 13 (24%) n = 7 (24%) 0
Arrhythmic death /resuscitated cardiac arrest n = 11 (30%) n = 20 (37%) n = 9 (31%) 0 LVEF, left ventricular ejection fraction. Crea_I1, mg/dL, Med 150
LVEF, left ventricular ejection fraction; VT, ventricular tachycardia; LF, low-frequency; HF, high-frequency; PVS, programmed ventricular stimulation; SAECG, signal-averaged ECG; MTWA, microvolt T-wave alternans. Data are n (%), unless otherwise indicated; Med = median (Q1-Q3); I1, I2 Investigation 1 and 2; N is the number of non-missing values; test used: Kruskal-Wallis test primary prevention studies the absolute reduction in total mortality in the ICD groups was as low as 5% and 5Á6%, respectively [3, 16] . In the SCD-Heft Trial, in ischemic heart disease patients, the difference in total mortality reached borderline significance (P = 0Á05) only [16] . If all our study patients, irrespective of the degree of left ventricular dysfunction, would have undergone primary prophylactic ICD implantation, the treatment ratio would have been 3 : 1 as there were 40 arrhythmic deaths or resuscitated cardiac arrest events. In addition, if one considers non-fatal VT in the setting of ischemic heart disease, an indication for ICD implantation, the percentage of patients benefitting from ICD therapy would increase to 44% with a treatment ratio of 2Á3 : 1.
Among all other non-invasive tests applied in this study, only an abnormal MTWA test was found to be able to identify patients at risk of arrhythmic death although with false-negative test results in 11% of cases which makes its applicability in clinical practice questionable. Furthermore, the possible significant advantage of MTWA becomes less evident in a Cox proportionalhazards model and the related likelihood ratio test. In addition, patients with known atrial fibrillation were not included and 8Á2% of study patients could not be tested due to atrial fibrillation.
In the REFINE study, neither MTWA nor other non-invasive markers were found to be predictive for the primary outcome as stand-alone tests [7] . The REFINE study found that only a combination of at least two tests predicted a significantly higher independent risk for the primary outcome 10-14 weeks after myocardial infarction. Main differences compared to our study were as follows: tests at 2-4 and 10-14 weeks after myocardial infarction, study population size, no control group and the median follow-up of 1Á9 years with an event rate of 9Á4% compared to an event rate of 66% in the underlying study.
Neither SAECG nor the presence of nsVT on Holter recordings was found to be useful in fatal arrhythmic risk prediction. Also programmed ventricular stimulation with its high amount of false-negative test results should therefore no longer be recommended for risk stratification. The markers of autonomic tone, HRV and BRS, were predictive for CD but not so for AD or RCA and therefore also should not be used for risk stratification. Rationale for combined and multiple assessment
Our primary endpoint was AD or RCA. This is in contrast to many other studies using sudden death as endpoint that is not synonymous with a fatal ventricular tachyarrhythmia. The rational for multiple testing and a projected follow-up of 10 years was the generally low risk of fatal arrhythmias in post-MI patients [17] , which significantly increases approximately 20 months after myocardial infarction [18] . In addition, this study aimed to achieve a high rate of endpoints to sufficiently support statistical analysis. In fact, there was an event rate of 66% in ischemic heart disease patients (79/120 patients). This high event rate was driven by (i) the very long follow-up period, (ii) the large percentage of implanted ICDs which allowed an increased event detection and (iii) similar demographics to other landmark studies making data comparable. The reason to choose an upper LVEF limit of 50% was based on the ATRAMI study [4] , where a relative risk of 2Á5 for cardiac mortality in patients with an LVEF between 35% and 50% compared with patients with LVEF > 50% was found.
Study limitations
This was a non-randomized, prospective, observational study performed to assess the risk of fatal arrhythmias during longterm follow-up. It is still possible that some of the events, defined as RCA, might not have led to death. Another limitation is the small sample size, which does not allow making firm conclusions. Based on our power calculation, our study has sufficient power of 89% to reject the null hypothesis that the survival curves are equal between ischemic heart disease patients and controls. Additionally, we introduced Figure 2 (a-f) Kaplan-Meier curves show the association between non-invasive tests (MTWA, BRS, LVEF and SDNN) and secondary endpoint (a, cardiac death) and primary endpoints (b-f, arrhythmic death, resuscitated cardiac arrest) for ischemic heart disease patients.
multivariable adjustment using Cox proportional-hazards model to study multiple parameters to gain statistical power.
There is a potential beta error which is a limitation of the present study. This can be only investigated in a bigger population in the future. Therefore, any finding should be labelled as pilot study results and only randomized ICD trials can give definite answers about the true value of risk stratification.
Conclusion
Patients with ischemic heart disease and rather preserved left ventricular function carry the same risk of fatal arrhythmic events as those with markedly reduced left ventricular function. None of the available risk stratification techniques (single or combination rules) reliably can identify patients at risk for arrhythmic events. Therefore, the current practice to constrain prophylactic ICDs to patients with severely reduced LVEF seems to be insufficient. 
